20 August 2024
N4 Pharma plc
("N4 Pharma" or the "Company")
SRI research Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to provide an update on its work with SRI International ("SRI").
Further to the Company's announcement on 25 April 2024, SRI has successfully completed the chemistry work and shown that a Fox Three Molecular Guidance System ("MGS") can be added to Nuvec® without altering its loading capability. SRI has then attached an siRNA compound to the combined Nuvec® / Fox three MGS and demonstrated that this is clearly internalized into only the targeted cell type.
The next step is to show that this siRNA still retains its functionality in the target cell.
Find more information and an additional video by Nigel Theobald, CEO and submit any questions via the N4 Pharma investor hub: https://investors.n4pharma.com/link/VyEgmr.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"This is an exciting development for us as it clearly shows that Nuvec® is capable of targeting specific cells via the addition of a relevant ligand, something the industry is actively looking for.
"We will now start working on a combined marketing pitch deck allowing SRI and N4 Pharma to present this data and its implications to major pharma and biotech players that need a targeting delivery system for their nucleic acid programs."
For more information please contact:
| N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director
Engage with us directly at N4 Pharma Investor Hub
To hear more, visit |
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
|
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44(0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44(0)20 3657 0050 |
| | |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.
N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
